Senior promotions for PTC Therapeutics

New Jersey’s PTC Therapeutics has made a double senior appointment.

Matthew Klein has been promoted to Chief Development Officer and Eric Pauwels to Chief Business Officer.

Dr. Klein will be responsible for the development of our clinical stage programs.

As the Chief Business Officer, Mr. Pauwels will be responsible for our customer facing activities with health care providers, patients and payers ensuring that our therapies are available and accessible to rare disease patients and their families worldwide.

“In their new roles, they will continue to advance our development pipeline, fuel our company’s growth and deliver on our mission to develop and provide transformative therapies for patients living with rare disorders,” said CEO Stuart Peltz.

Dr Klein joined PTC last year as Global Head of Gene & Mitochondrial Therapies after serving as CEO and Chief Medical Officer of BioElectron Technology Corporation, certain assets of which were acquired by PTC in 2019.

Prior to leading BioElectron, he was the Auth-Washington Research Chair of Restorative Burn Surgery at the University of Washington.

Mr Pauwels joined PTC in 2015 as Senior Vice President and General Manager of the Americas, overseeing commercial strategy and market access.

Prior, he served as the Chief Commercial Officer at NPS Pharmaceuticals and President of NPS Pharma International.

Previously, he served as Senior Vice President of Global Commercial Operations at Shire Human Genetic Therapies.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...